Premium Ubrogepant API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Ubrogepant (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist

Indications: Acute Treatment of Migraine

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Ubrogepant distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Ubrogepant is an orally bioavailable, small-molecule Active Pharmaceutical Ingredient (API). In neurology and pain management pharmacology, it is classified as a calcitonin gene-related peptide (CGRP) receptor antagonist, frequently referred to within the "gepant" drug class.

During a migraine attack, the trigeminal nerve system releases elevated levels of CGRP, a potent neuropeptide that binds to specific receptors on intracranial blood vessels and mast cells. This binding triggers severe neurogenic inflammation and pronounced vasodilation, which are the primary physiological drivers of migraine pain.

Ubrogepant functions by competitively binding to the CGRP receptor, effectively blocking the endogenous peptide from initiating this inflammatory cascade. Unlike legacy acute migraine treatments (such as triptans or ergotamines), Ubrogepant achieves pain relief without inducing direct vasoconstriction. This distinct pharmacological profile provides formulation scientists with the opportunity to develop highly effective migraine therapeutics that are safe for patients with underlying cardiovascular or cerebrovascular contraindications.

In finished pharmaceutical products, Ubrogepant is typically formulated into immediate-release 50 mg and 100 mg oral solid dosage forms.

Sourcing Ubrogepant in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced neurological formulations requires a highly resilient and traceable raw material pipeline. Procuring specialty neurological APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. Sourcing Ubrogepant Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you require a standard batch or are scaling up a high-volume Ubrogepant api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages or raw material shortages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during blending and tablet compression processes.

Technical Specifications for QA & R&D

The Ubrogepant API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: (6S)-N-[(3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide
• CAS Number: 1374248-77-7
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C29H26F3N5O3
• Molecular Weight: 549.55 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Soluble in specific organic solvents (such as DMSO); practically insoluble in water. Detailed solubility parameters and pKa values across standard solvents and aqueous buffers are documented in the technical data sheet to assist analytical R&D teams with dissolution profiling.

Manufacturing and Handling Guidelines for Formulators

Ubrogepant is a targeted neurological therapeutic compound. Facilities processing this API must enforce standard occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature or refrigerated at 2-8°C depending on the specific stability data, strictly protected from excessive heat and humidity) to prevent chemical degradation.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or respirators, chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure weighing booths to prevent the inhalation of airborne particulates and facility cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.